GlassScriptPhysician profile
Jennifer Aileen Calabrese
NPI 1053523340
$9,840.38
in general payments reported to CMS, 2019-2025
56 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,420 · 2020: $819 · 2021: $1,229 · 2022: $1,248 · 2023: $1,625 · 2024: $1,091 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,123.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,822.35 | 2019-2025 | |
| Novo Nordisk INC | $988.05 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $968.76 | 2019-2025 | Vraylar, Viberzi, Linzess |
| Glaxosmithkline, LLC. | $636.39 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $615.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $354.22 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $310.34 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $289.82 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.42 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.57 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $227.02 | 2019-2025 | Gardasil 9, Proquad, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $222.94 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $209.75 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.28 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.23 | 2019-2024 | Xifaxan, Trulance |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Calabrese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.